PCSK9对糖尿病心肌病的影响:机制和影响
Haixia Wang1, Pei Wang1, Yubo Wang1
1The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China.
Biomolecules
|September 27, 2025
概括
蛋白转化酶亚素/素9型 (PCSK9) 通过恶化炎症和代谢问题驱动糖尿病心肌病 (DCM). PCSK9抑制剂在2型糖尿病 (T2DM) 患者中可能为DCM提供治疗效益.
科学领域:
- 心血管医学 心血管医学
- 代谢障碍 代谢障碍 代谢障碍
- 分子生物学分子生物学
背景情况:
- 糖尿病心肌病 (DCM) 是糖尿病的一个关键并发症,在没有其他常见原因的情况下引起心脏功能障碍.
- 益蛋白转化酶亚素/素9型 (PCSK9) 越来越被认为是DCM发展的关键因素.
- PCSK9影响脂质代谢,炎症和细胞过程,如自,所有这些都与DCM相关.
研究的目的:
- 审查PCSK9在糖尿病心肌病变的发病过程中的机制性作用.
- 探索针对PCSK9在2型糖尿病 (T2DM) 患者中进行DCM管理的治疗潜力.
- 突出PCSK9作为T2DM中心血管风险的潜在生物标志物.
主要方法:
- 关于PCSK9,DCM和T2DM的最新研究的文献综述.
- 在代谢和炎症途径中分析PCSK9与受体 (LDLR,CD36,TLR4) 的相互作用.
- 综合证据表明PCSK9与心肌功能障碍,炎症,热和DCM中的自有关.
主要成果:
- 在DCM中,PCSK9会加剧炎症和热,并与自功能受损有关.
- 升高的PCSK9水平是T2DM心血管事件的潜在生物标志物.
- PCSK9抑制剂 (PCSK9i) 是有前途的,长期研究中没有观察到糖尿病发病率的显著增加.
结论:
- PCSK9在DCM病变发生过程中发挥着多方面的作用,影响脂质,代谢和炎症途径.
- 向PCSK9代表了T2DM中心血管风险管理的潜在策略.
- 需要进一步的研究来充分阐明PCSK9在心脏代谢调节中的复杂作用.
相关概念视频
01:30Coronary Artery Disease I: Introduction
882
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
882
01:30Cardiomyopathy II: Dilated Cardiomyopathy
470
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
470
01:29Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
411
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
411
01:25Cardiomyopathy I: Introduction and Classification
504
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
504
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
455
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
455